Pulmonary Function Testing (PFT) is a vital tool in diagnosing and managing respiratory diseases. However, interpreting the results can be complex for healthcare professionals. This guide aims to simplify the process.
Spirometry, the most common PFT, measures the amount (volume) and speed (flow) of air that can be inhaled and exhaled. Key values include Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and their ratio (FEV1/FVC). Abnormalities in these values can indicate obstructive or restrictive lung diseases.
Obstructive disorders, such as COPD and asthma, are characterized by reduced airflow. This is reflected in a decreased FEV1/FVC ratio. On the other hand, restrictive disorders like pulmonary fibrosis present with reduced lung volumes (FVC), but normal or increased FEV1/FVC ratio.
Gas exchange tests, such as the diffusion capacity for carbon monoxide (DLCO), provide insight into the lung’s ability to transfer gases between the alveoli and the bloodstream. Reduced DLCO can indicate diseases like emphysema or pulmonary hypertension.
Interpretation of PFT results should always be integrated with the patient's symptoms, physical examination, and other diagnostic tests. For instance, a reduced FEV1/FVC ratio accompanied by wheezing and episodic breathlessness may suggest asthma.
Interpreting PFT results is a nuanced process that requires a comprehensive understanding of respiratory physiology and clinical context. By understanding spirometry and gas exchange testing, and recognizing obstructive and restrictive patterns, healthcare professionals can more accurately diagnose and manage respiratory diseases.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation